1-15 of 15
Cyril H. Benes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Qibiao Wu, Yuanli Zhen, Lei Shi, Phuong Vu, Patricia Greninger, Ramzi Adil, Joshua Merritt, Regina Egan, Meng-Ju Wu, Xunqin Yin, Cristina R. Ferrone, Vikram Deshpande, Islam Baiev, Christopher J. Pinto, Daniel E. McLoughlin, Charlotte S. Walmsley, James R. Stone, John D. Gordan, Andrew X. Zhu, Dejan Juric, Lipika Goyal, Cyril H. Benes, Nabeel Bardeesy
Journal: Cancer Discovery
Cancer Discov (2022) 12 (5): 1378–1395.
https://doi.org/10.1158/2159-8290.CD-21-1168
Published: 02 May 2022
View article titled, EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
Open the PDF for EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James R. Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (1): 72–85.
https://doi.org/10.1158/2159-8290.CD-18-0830
Published: 09 January 2020
View article titled, PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Open the PDF for PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Lipika Goyal, Lei Shi, Leah Y. Liu, Ferran Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W.S. Ng, Phuong Vu, Krushna C. Patra, Supriya K. Saha, Raul N. Uppot, Ron Arellano, Stephanie Reyes, Takeshi Sagara, Sachie Otsuki, Brandon Nadres, Heather A. Shahzade, Ipsita Dey-Guha, Isobel J. Fetter, Islam Baiev, Emily E. Van Seventer, Janet E. Murphy, Cristina R. Ferrone, Kenneth K. Tanabe, Vikram Deshpande, James J. Harding, Rona Yaeger, Robin K. Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (8): 1064–1079.
https://doi.org/10.1158/2159-8290.CD-19-0182
Published: 01 August 2019
View article titled, TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Open the PDF for TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes, Gordon Moody, Kathleen S. Keegan, Danny Chui, Douglas A. Whittington, Xin Huang, Leszek Poppe, Alan C. Cheng, Mario Cardozo, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A. Paras, Xianghong Wang, Joshua P. Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng Zhu, Elaina Cajulis, Tao Osgood, Jan Sun, Leah Damon, Regina K. Egan, Patricia Greninger, Joseph D. McClanaghan, Jianan Gong, Donia Moujalled, Giovanna Pomilio, Pedro Beltran, Cyril H. Benes, Andrew W. Roberts, David C. Huang, Andrew Wei, Jude Canon, Angela Coxon, Paul E. Hughes
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (12): 1582–1597.
https://doi.org/10.1158/2159-8290.CD-18-0387
Published: 03 December 2018
View article titled, AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Open the PDF for AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies in another window
Includes: Multimedia, Supplementary data
Journal Articles

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer

Varuna Nangia, Faria M. Siddiqui, Sean Caenepeel, Daria Timonina, Samantha J. Bilton, Nicole Phan, Maria Gomez-Caraballo, Hannah L. Archibald, Chendi Li, Cameron Fraser, Diamanda Rigas, Kristof Vajda, Lorin A. Ferris, Michael Lanuti, Cameron D. Wright, Kevin A. Raskin, Daniel P. Cahill, John H. Shin, Colleen Keyes, Lecia V. Sequist, Zofia Piotrowska, Anna F. Farago, Christopher G. Azzoli, Justin F. Gainor, Kristopher A. Sarosiek, Sean P. Brown, Angela Coxon, Cyril H. Benes, Paul E. Hughes, Aaron N. Hata
Journal: Cancer Discovery
Cancer Discov (2018) 8 (12): 1598–1613.
https://doi.org/10.1158/2159-8290.CD-18-0277
Published: 03 December 2018
View article titled, Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <em>KRAS</em>-Mutant Non–Small Cell Lung Cancer
Open the PDF for Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <em>KRAS</em>-Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman, Ted W. Johnson, Aaron N. Hata, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2018) 8 (6): 714–729.
https://doi.org/10.1158/2159-8290.CD-17-1256
Published: 31 May 2018
View article titled, Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer
Open the PDF for Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth Lockerman, Tiffany Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba Digumarthy, Colleen Channick, Colleen Keyes, Gad Getz, Dora Dias-Santagata, Rebecca S. Heist, Jochen Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2016) 6 (10): 1118–1133.
https://doi.org/10.1158/2159-8290.CD-16-0596
Published: 02 October 2016
View article titled, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer
Open the PDF for Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Supriya K. Saha, John D. Gordan, Benjamin P. Kleinstiver, Phuong Vu, Mortada S. Najem, Jia-Chi Yeo, Lei Shi, Yasutaka Kato, Rebecca S. Levin, James T. Webber, Leah J. Damon, Regina K. Egan, Patricia Greninger, Ultan McDermott, Mathew J. Garnett, Roger L. Jenkins, Kimberly M. Rieger-Christ, Travis B. Sullivan, Aram F. Hezel, Andrew S. Liss, Yusuke Mizukami, Lipika Goyal, Cristina R. Ferrone, Andrew X. Zhu, J. Keith Joung, Kevan M. Shokat, Cyril H. Benes, Nabeel Bardeesy
Journal: Cancer Discovery
Cancer Discov (2016) 6 (7): 727–739.
https://doi.org/10.1158/2159-8290.CD-15-1442
Published: 30 June 2016
View article titled, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Open the PDF for Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis

Capucine Van Rechem, Joshua C. Black, Myriam Boukhali, Martin J. Aryee, Susanne Gräslund, Wilhelm Haas, Cyril H. Benes, Johnathan R. Whetstine
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (3): 255–263.
https://doi.org/10.1158/2159-8290.CD-14-1326
Published: 05 March 2015
View article titled, Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis
Open the PDF for Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis in another window
Includes: Supplementary data
Journal Articles

A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors

Capucine Van Rechem, Joshua C. Black, Patricia Greninger, Yang Zhao, Carlos Donado, Paul d. Burrowes, Brendon Ladd, David C. Christiani, Cyril H. Benes, Johnathan R. Whetstine
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (3): 245–254.
https://doi.org/10.1158/2159-8290.CD-14-1159
Published: 05 March 2015
View article titled, A Coding Single-Nucleotide Polymorphism in Lysine Demethylase <em>KDM4A</em> Associates with Increased Sensitivity to mTOR Inhibitors
Open the PDF for A Coding Single-Nucleotide Polymorphism in Lysine Demethylase <em>KDM4A</em> Associates with Increased Sensitivity to mTOR Inhibitors in another window
Includes: Supplementary data
Journal Articles

EMT Twists the Road to PI3K

Matthew J. Niederst, Cyril H. Benes
Journal: Cancer Discovery
Cancer Discov (2014) 4 (2): 149–151.
https://doi.org/10.1158/2159-8290.CD-13-1030
Published: 04 February 2014
View article titled, EMT Twists the Road to PI3K
Open the PDF for EMT Twists the Road to PI3K in another window
Journal Articles

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Anthony C. Faber, Erin M. Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J. Edelman, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2014) 4 (1): 42–52.
https://doi.org/10.1158/2159-8290.CD-13-0315
Published: 07 January 2014
View article titled, mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <em>KRAS</em> or <em>BRAF</em> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Open the PDF for mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <em>KRAS</em> or <em>BRAF</em> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 in another window
Includes: Supplementary data
Journal Articles

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Alexandre Puissant, Stacey M. Frumm, Gabriela Alexe, Christopher F. Bassil, Jun Qi, Yvan H. Chanthery, Erin A. Nekritz, Rhamy Zeid, William Clay Gustafson, Patricia Greninger, Matthew J. Garnett, Ultan McDermott, Cyril H. Benes, Andrew L. Kung, William A. Weiss, James E. Bradner, Kimberly Stegmaier
Journal: Cancer Discovery
Cancer Discov (2013) 3 (3): 308–323.
https://doi.org/10.1158/2159-8290.CD-12-0418
Published: 07 March 2013
View article titled, Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Open the PDF for Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition in another window
Includes: Supplementary data
Journal Articles

Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma

Lei He, Kristine Torres-Lockhart, Nicole Forster, Saranya Ramakrishnan, Patricia Greninger, Mathew J. Garnett, Ultan McDermott, Stephen M. Rothenberg, Cyril H. Benes, Leif W. Ellisen
Journal: Cancer Discovery
Cancer Discov (2013) 3 (3): 324–337.
https://doi.org/10.1158/2159-8290.CD-12-0417
Published: 07 March 2013
View article titled, Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma
Open the PDF for Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, Joao Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry L. Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias-Santagata, Rakesh K. Jain, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2011) 1 (4): 352–365.
https://doi.org/10.1158/2159-8290.CD-11-0106
Published: 14 September 2011
View article titled, BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Open the PDF for BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors in another window
Includes: Multimedia, Supplementary data